NCT06929637 (AID-KT) is a NA clinical trial of Infusion Therapy in Short-term Graft Function, sponsored by University Hospital, Martin.

Who is sponsoring NCT06929637?

NCT06929637 is sponsored by University Hospital, Martin.

What drugs are being tested in NCT06929637?

Interventions in NCT06929637: Infusion Therapy, Saline solution infusion.

What condition does NCT06929637 study?

NCT06929637 studies Short-term Graft Function, Metabolic Effects, Nutritional Effect, Immunological &Amp; Inflammatory Markers, Safety, Adverse Events.

Is NCT06929637 still recruiting?

NCT06929637 is currently not yet recruiting. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT06929637: AID-KT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amino Acid Infusion in Kidney Transplant Recipients

Not yet recruiting NA Last updated 16 April 2025

What this trial tests

NA trial testing Infusion Therapy in Short-term Graft Function in 100 participants. Not yet recruiting.

Timeline

15 September 2025

Primary endpoint
15 September 2028

1 January 2029

Quick facts

Lead sponsor	University Hospital, Martin
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	100
Start date	15 September 2025
Primary completion	15 September 2028
Estimated completion	1 January 2029
Sites	1 location across Slovakia

Drugs / interventions tested

Infusion Therapy — full drug profile →
Saline solution infusion

Conditions studied

Short-term Graft Function — all drugs for Short-term Graft Function →
Metabolic Effects — all drugs for Metabolic Effects →
Nutritional Effect — all drugs for Nutritional Effect →
Immunological &Amp; Inflammatory Markers — all drugs for Immunological &Amp; Inflammatory Markers →

Sponsor

University Hospital, Martin

Who can join

18 and older, any sex, with Short-term Graft Function or Metabolic Effects. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study addresses the impact of amino acid infusion in the early post-transplant period on graft function and the incidence of post-transplant complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital, Martin trials

Trials by the same sponsor.

NCT07274462 — DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) · Phase 4 · active not recruiting
NCT07338929 — Physical Performance Assessment in Kidney Transplant Evaluation · recruiting
NCT07081126 — Daratumumab for Late Antibody-Mediated Rejection · NA · recruiting
NCT07055984 — Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA · recruiting
NCT07024238 — Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06929637 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Martin
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06929637.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing